12月23日港股通创新药ETF工银(159217)遭净赎回2524.06万元

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced significant net redemptions, indicating a trend of outflows from this fund in recent trading days [1][2] Group 1: Fund Performance - On December 23, the fund faced net redemptions of 25.24 million yuan, ranking 7th in net outflows among cross-border ETFs [1] - Over the past 5 days, the fund saw net redemptions totaling 27.89 million yuan, ranking 11th in net outflows [1] - The fund's total assets under management as of December 23 were 5.078 billion yuan, down from 5.1 billion yuan the previous day, reflecting a 0.49% outflow relative to the prior day's size [1] Group 2: Fund Details - The fund was established on March 26, 2025, with an annual management fee of 0.40% and a custody fee of 0.07% [1] - The current fund managers are Liu Weilin and Jiao Wenlong, with returns of 32.75% and 51.30% respectively since their management began [2] Group 3: Holdings and Composition - Major holdings in the fund include companies such as BeiGene (10.84%), CanSino Biologics (10.77%), and Innovent Biologics (10.43%), with respective market values of 589 million yuan, 586 million yuan, and 567 million yuan [2] - The fund tracks the Hong Kong Stock Connect Innovative Drug Index (987018) [1][2] Group 4: Comparative Analysis - Other ETFs tracking the same index include Huatai-PineBridge, Southern, and Penghua, with varying sizes and liquidity metrics [2] - As of December 23, the fund's average daily trading volume over the last 20 trading days was 485 million yuan [2]